Evaluating in-licensing & trademark process in pharmaceutical industry
01/04/2020
Currently one of our clients is looking to connect with senior experts from leading pharmaceutical companies in India. They are trying to understand the approximate upfront payment required while in-licensing a molecule and any additional cost required to buy the trademark brand name. Experts from prominent players such as Zydus, DRL, Novartis, MSD, BI, Cipla, Ranbaxy, Sun, GSK, etc will be preferred.
